Bayer's €5bn Legal Bill Casts a Long Shadow Over Patchy Operational Gains
17.06.2026 - 08:05:44 | boerse-global.de
Bayer’s stock sits at €35.91, a whisker below its 200-day moving average of €36.07 and roughly 28% off the February peak of €49.93. That is a stark gap for a share that has rallied more than 43% from its August 2025 trough and posted a 33% gain over the past twelve months. The divergence tells the real story: optimism about a turnaround has faded as the hard realities of debt and litigation reassert themselves.
The most immediate drag is cash. Chief Financial Officer Wolfgang Nickl expects around €5bn to flow out of the company in 2026 solely to cover legal settlements and defence costs. Free cash flow is forecast to slide into negative territory, landing between minus €2.5bn and minus €1.5bn. Net financial debt could hit €32bn to €33bn by year-end. Those are not footnotes; they are structural handcuffs that severely limit the conglomerate’s financial flexibility.
On the operational side, there are genuine bright spots. The pharma division has gained traction, with a new MRI contrast agent approved in the United States and an expanded label for the cancer drug Nubeqa in China. Bayer expects several milestones this year in cardiovascular and oncology programmes, and from 2027 it sees mid-single-digit growth and improving margins in the segment. The agricultural unit, Crop Science, has launched a five-year overhaul and is reporting early progress. For 2026, the group expects stronger contributions from both agriculture and Consumer Health to offset a softer pharma result, keeping overall business performance broadly stable. Cost-savings from restructuring are also set to reach billions by the end of the year.
Should investors sell immediately? Or is it worth buying Bayer?
None of that, however, has shifted the market’s focus. The legal overhang from glyphosate claims in the US continues to dominate sentiment. Provisions and settlements pushed the company deep into the red on a net basis in 2025, and clarity on the litigation front remains elusive. Some investors are pressing for a formal review of the corporate structure, with a speculative spin-off of the Consumer Health unit floated as an option. Yet management, led by CEO Bill Anderson, has so far resisted a breakup, insisting that operational improvement is the priority. The problem is that without a resolution on the legal front, the catalyst for any structural shake-up is deferred.
The stock’s technical picture reflects the uncertainty. The 30-day annualised volatility stands above 30%, and the relative strength index at 44.2 sits in neutral territory — neither panic nor conviction. Since the start of the year, the shares are down roughly 5% to 6%, wiping out a chunk of the earlier recovery. The market is effectively pricing in a waiting game.
Bayer is not a hopeless case. The product pipeline is strengthening, management has begun reshaping the business, and the valuation is far less stretched than at its August 2025 low. But the path to a genuine re-rating runs directly through the twin questions of debt control and legal certainty. Without a visible plan to shrink the litigation burden, the operational improvements will struggle to lift the equity. The second half of 2026 will provide several checkpoints on Anderson’s promises — and on whether this is a recovery in the making or a mirage that investors have already started to walk away from.
Ad
Bayer Stock: New Analysis - 17 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
